High-power laser system approved for BPH treatment
San Jose, CA-Laserscope has received FDA approval to market a high-power KTP laser system for photoselective vaporization of the prostate for the treatment of BPH. The product uses an 80-watt KTP/532 laser system and sterile, disposable, fiber-optic delivery devices. During the procedure, a miniature camera attached to an endoscope is inserted through the urethra to the prostate. A laser fiber is threaded through the endoscope to the area to be treated. The laser, which operates at 532 nm, is then used to vaporize excess tissue. The minimally invasive procedure can be performed on an outpatient basis, the company says.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.